ADMdx Logo

Remarkable Clarity

in the diagnosis and treatment of brain disorders through advanced imaging biomarkers
  • ADMdx patient and caregiver

Defining clarity in diagnostics

At ADMdx, we’re applying advances in image measurement, analysis, and AI to support earlier, more accurate identification of brain disorders, including Alzheimer’s disease and other dementias.

CorInsights® MRI, our first FDA 510k cleared product, is powered by ADMdx technology. This advanced reporting tool uses readily available MRI brain scans to support medical professionals in providing a new standard of care.


Enabling success in clinical trials

ADMdx provides a full spectrum of imaging CRO services for CNS imaging trials using PET and MRI biomarkers, including:

  • Protocol input, charter and technical manual development
  • Imaging site identification and qualification
  • Central data receipt and quality control
  • Radiology reads
  • Advanced image processing and analysis
  • Reporting
  • Data management and archival

We support clinical trial success by combining key elements of CLARITY, QUALITY, PARTNER FOCUS, and INSIGHT.

Using our reference database and multivariate image classification, we address critical questions to support trial success:

  • Patient inclusion based upon:
    • Disease patterns
    • Pathology
  • Patient stratification for analysis, by predicting:
    • Rates of clinical decline
    • Pathology accumulation rates
  • Detection of treatment effect
  • Treatment responder characteristics

Learn more about our clinical trial capabilities.

Harnessing the power of  imaging for UNPARALLELED INSIGHTS

Using our reference database of tens of thousands of PET and MRI scans with associated clinical and fluid biomarker data and through long-standing collaborations with thought leaders from major institutions, ADMdx has characterized the effects of diseases and syndromes, including:

  • Alzheimer’s disease progression from amyloid-negative controls through amyloid and tau-positive AD dementia
  • Atypical Alzheimer’s disease variants, including Posterior Cortical Atrophy, amyloid-positive Corticobasal Syndrome, and amyloid positive Logopenic Progressive Aphasia, and Early Onset Alzheimer’s Disease
  • Frontotemporal dementia variants, including behavioral, semantic dementia, primary progressive aphasia, and nonfluent progressive aphasia
  • Traumatic brain injury
  • Parkinson’s disease
  • White matter / cerebrovascular disease
  • Down Syndrome

Join us for ongoing updates, including webinar sessions, group calls, user experience surveys and more.

ADMdx Logo
©2023. CorInsights® MRI is a registered trademark of AMDdx, 555 Skokie Blvd, Suite 500, Northbrook, IL, 60062, USA.